Protagonist Therapeutics, Inc
PTGX Nasdaq
SEC CIK 1377121
Follow Protagonist Therapeutics
Weekly email: filings, results
Revenue, last quarter
$274.4M
+5723.6% vs same quarter last year
Net income
$220M
+659.3% vs same quarter last year
EPS, diluted
$3.07
+595.2% vs same quarter last year
Operating cash flow
−$23.2M
−1098.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $46M | −$130.1M |
| FY24 | $434.4M | $275.2M |
| FY23 | $60M | −$79M |
| FY22 | $26.6M | −$127.4M |
| FY21 | $27.4M | −$125.6M |
| FY20 | $28.6M | −$66.2M |
| FY19 | $231K | −$77.2M |
| FY18 | $30.9M | −$38.9M |
| FY17 | $20.1M | −$37M |
| FY16 | - | −$37.2M |
| FY15 | - | −$14.9M |
| FY14 | - | −$11.1M |
| FY13 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −343.6% | −282.8% |
| FY24 | 58.2% | 63.3% |
| FY23 | −156.1% | −131.6% |
| FY22 | −494.2% | −479.3% |
| FY21 | −460% | −458.9% |
| FY20 | −225.4% | −231.1% |
| FY19 | −34857.6% | −33414.3% |
| FY18 | −136.7% | −125.9% |
| FY17 | −188.9% | −184.2% |
| FY16 | - | - |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $56.1M |
| FY24 | $182.8M |
| FY23 | −$70.8M |
| FY22 | −$108.9M |
| FY21 | −$109M |
| FY20 | −$73M |
| FY19 | −$42.5M |
| FY18 | −$50.4M |
| FY17 | $3.2M |
| FY16 | −$30.3M |
| FY15 | −$14.8M |
| FY14 | −$8M |
| FY13 | - |
- Protagonist Therapeutics
- Healthcare median
Show the numbers
| Year | Protagonist Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −282.8% | −30.6% |
| FY24 | 63.3% | −47% |
| FY23 | −131.6% | −58% |
| FY22 | −479.3% | −80.4% |
| FY21 | −458.9% | −71.9% |
| FY20 | −231.1% | −62.2% |
| FY19 | −33414.3% | −46.3% |
| FY18 | −125.9% | −49.6% |
| FY17 | −184.2% | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −38.4% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |